Economical impact of plasma fractionation project in Iran on affordability of plasma‐derived medicines

Transfusion Medicine - Tập 19 Số 6 - Trang 363-368 - 2009
Abdol Majid Cheraghali1, Reza Aboofazeli2
1Iranian Blood Transfusion Organization Research Center and Chemical Injury Research Center, University of Baqiyatallah Medical Sciences
2Iranian Blood Research and Fractionation Holding Company and School of Pharmacy, Shaheed Beheshti University of Medical Sciences, Tehran, Iran

Tóm tắt

summary.In Iran all transfusion services are concentrated under authority of one public and centralized transfusion organization which has created the opportunity of using plasma produced in its blood centers for fractionation. In 2008 voluntary and non remunerated Iranian donors donated 1.8 million units of blood. This indicates a 25/1000 donation index. After responding to the needs for fresh plasma and cryoprecipitate each year about 150000 L of recovered plasma are reserved for fractionation. In an attempt to improve both blood safety profile and availability and affordability of plasma derived medicines, Iran's national transfusion service has entered into a contract fractionation agreement for surplus of plasma produced from donated blood by voluntary non remunerated donors. In order to ensure safety of product produced, Iran has chosen to collaborate with international fractionators based in highly regulated countries. The main objective of this study was to evaluate the impact of contract plasma fractionation on the affordability of the plasma derived medicines in Iran. During 2006–2008, Iran's contract fractionation project was able to produce 46%, 18% and 6% of IVIG, Albumin and FVIII consumed in Iran's market, respectively. In contrary to IVIG and Albumin, due to fairly high consumption of FVIII in Iran, the role of fractionation project in meeting the needs to FVIII was not substantial. However, Iran's experience has shown that contract plasma fractionation, through direct and indirect effects on price of plasma derived medicines, could substantially improve availability and affordability of such products in national health care system.

Từ khóa


Tài liệu tham khảo

Abolghasemi H., 2009, Introduction to Iranian Blood Transfusion Organization and blood safety in Iran, Iranian Journal of Public Health, 38, 82

10.1016/j.puhe.2004.05.011

10.1046/j.1365-2516.1998.440481.x

Burnouf T., 2005, Plasma proteins: unique biopharmaceuticals‐unique economics, Pharmaceutical Policy and Law, 7, 209

10.1016/j.tmrv.2006.11.001

10.1016/j.tracli.2007.04.002

10.1016/j.transci.2007.03.013

10.1111/j.1365-2516.2008.01936.x

10.1111/j.1365-2516.2004.01007.x

10.1111/j.1365-2516.2004.00911.x

10.1016/j.biologicals.2009.01.005

10.1016/S1473-0502(02)00104-0

10.1182/blood-2005-04-1371

10.1111/j.1365-2516.2001.00468.x

WFH(2007 December) World Federation of Hemophilia Report on the Annual Global Survey 2006. URLhttp://www.wfh.org/2/7/7_0_Link7_GlobalSurvey2006.htm[Accessed 15th August 2009].

World Health Organization2005)WHO recommendations for the production control and regulation of human plasma for fractionation. URLhttp://www.who.int/bloodproducts/en/[Accessed 15th August 2009].

World Health Organization2008)Note prepared by HSS/EMP/QSM. 59th ECBS Meeting October 2008.

Thông tin
Thông tin xuất bản

Transfusion Medicine

Tập 19 Số 6

363-368

Thông tin tác giả